Straumann Holding AG stock (CH0012280076): dental implant specialist after 2024 results and acquisition push

Straumann Holding AG remains in focus after reporting solid 2024 results and advancing its clear-aligner and orthodontics strategy, including the GalvoSurge acquisition, putting the Swiss dental implant leader on the radar of international and US-focused investors.

Straumann Holding AG, a global leader in dental implants and orthodontics solutions, is drawing renewed investor attention after presenting its full-year 2024 results and highlighting continued expansion in clear aligners and digital dentistry, according to the company’s results release published on 02/20/2025 and subsequent investor materials Straumann investor information as of 02/20/2025 and coverage by Reuters as of 02/20/2025.

As of: 24.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Straumann
• Sector/industry: Dental implants, orthodontics, medical technology
• Headquarters/country: Basel, Switzerland
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Dental implants, clear aligners, orthodontics, digital dentistry solutions
• Home exchange/listing venue: SIX Swiss Exchange (ticker: STMN)
• Trading currency: Swiss franc (CHF)

Straumann Holding AG: core business model

Straumann focuses on premium and value dental implants, restorative components, clear aligners and orthodontic solutions for dentists and dental labs worldwide. The group positions itself as a comprehensive provider for tooth replacement and esthetic dentistry, spanning surgery, prosthetics, biomaterials and digital workflow tools. This integrated approach is designed to anchor the company deeply in dental practices.

The company’s strategy builds on close partnerships with dentists, orthodontists and dental service organizations, supported by training and education programs. Straumann distributes its products through a combination of direct sales organizations in key countries and distributors in smaller markets. The model targets recurring procedure-driven demand, as implants and orthodontic treatments are part of longer treatment plans rather than one-off product sales.

In addition to hardware like implants and abutments, Straumann has expanded into software, intraoral scanning and treatment planning platforms. These digital tools are meant to streamline case planning and enable more predictable outcomes, supporting cross-selling across the portfolio. The evolution from product supplier to solutions partner is a core pillar of Straumann’s long-term positioning in the dental technology landscape.

Main revenue and product drivers for Straumann Holding AG

Straumann’s largest revenue contributor remains dental implants and related components, where the company competes at the premium and value end of the market. According to its full-year 2024 results announcement released on 02/20/2025, Straumann reported continued organic growth in implantology, supported by procedure volume expansion and increased penetration of value brands in emerging markets Straumann investor information as of 02/20/2025. This segment benefits from demographic trends such as aging populations and higher expectations for oral health.

A second key driver is the clear aligner and orthodontics franchise, which Straumann has been building through its ClearCorrect brand and various acquisitions over recent years. In its 2024 report, the group highlighted strong growth in the aligner business and increased adoption among general practitioners, according to the same disclosure on 02/20/2025 Straumann investor information as of 02/20/2025. This area is strategically important as patients seek less invasive and more esthetic orthodontic options.

Digital dentistry and orthodontic solutions, including scanners, planning software and treatment platforms, represent another growth pillar. Straumann has invested in these technologies to support integrated workflows from diagnosis to restoration. The company also reports recurring revenue from treatment planning, service contracts and consumables associated with digital solutions, although hardware sales remain a visible component in its revenue mix.

Geographically, Straumann generates a significant share of its revenue in Europe and North America, with the United States named as a core growth region in the 2024 full-year commentary released on 02/20/2025 Reuters as of 02/20/2025. Asia-Pacific, particularly China, also contributes meaningfully and can lead to regional volatility when regulatory or demand conditions change.

Why Straumann Holding AG matters for US investors

Although Straumann is listed on the SIX Swiss Exchange rather than a US exchange, its footprint in the United States is strategically important. The company notes in its 2024 results release dated 02/20/2025 that North America, including the US, remains a core region for implant and aligner growth, benefiting from high per-capita dental spending and established dental service organizations Straumann investor information as of 02/20/2025. For US investors, Straumann offers exposure to procedural dental care trends that complement domestic players.

The company competes with large US-listed dental firms in implants, aligners and digital solutions, and its performance can provide additional signals about global demand for dental procedures. US-focused portfolios with an international allocation may see Straumann as a way to diversify within the medical technology and dental segment. Currency moves between the Swiss franc and the US dollar are also relevant for American investors assessing returns in their home currency.

Institutional investors in the US often monitor Straumann’s comments about patient traffic, treatment acceptance and elective spending, as these can reflect broader consumer confidence and the willingness to undertake out-of-pocket medical and esthetic procedures. In this sense, Straumann’s disclosures may carry informational value beyond the stock itself, adding context for the wider dental and medtech industry in North America.

Conclusion

Straumann Holding AG remains a key global player in dental implants and orthodontics, supported by its 2024 results and ongoing investments in clear aligners and digital dentistry. The company’s geographic diversification, including a material presence in the US market, offers exposure to structural trends in dental care. At the same time, investors must weigh factors such as competitive intensity, regulatory developments and macro-sensitive demand for elective procedures. As always, an independent assessment of the risk-return profile and alignment with individual investment objectives is essential when considering any exposure to Straumann or the wider dental technology sector.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.